WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) I L.P. reported 2 transactions at VERVE THERAPEUTICS, INC.
Review the transaction codes below to understand the nature of each event.
Filed: 6/22/2021ACC: 0000899243-21-025303
→
10% Owner
Since Jun 2021
-20.61M
Net shares
Net seller
$0.00
Total acquired
0
Open market trades
0B · 0S
4
Total transactions
2.50M acquired · 23.11M disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+1.34M
Price / share
—
Trade value
—
% of position
New position
6/21/2021
0.00→1.34M
Common Stock
Direct
Shares
+1.15M
Price / share
—
Trade value
—
% of position
85.8%
6/21/2021
1.34M→2.50M
Total
Net shares
+2.50M
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/21/2021 | C · Conversion | +1.34M | — | — | New position | 0.00 | 1.34M |
| Common Stock Direct | 6/21/2021 | C · Conversion | +1.15M | — | — | 85.8% | 1.34M | 2.50M |
| Total | +2.50M | $0.00 | ||||||
Derivative Transactions2
Series A-2 Preferred Stock
Direct
Converts to
Common Stock
1.34M shares
Shares
−12.44M
Strike price
Held after
0.00
Exercisable
—
6/21/2021
Series B Preferred Stock
Direct
Converts to
Common Stock
1.15M shares
Shares
−10.67M
Strike price
Held after
0.00
Exercisable
—
6/21/2021
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Series A-2 Preferred Stock Direct | Common Stock1.34M shares | 6/21/2021 | C · Conversion | −12.44M | — | 0.00 | |
| Series B Preferred Stock Direct | Common Stock1.15M shares | 6/21/2021 | C · Conversion | −10.67M | — | 0.00 |